Mode of antiviral action of silver nanoparticles against HIV-1

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  Lara, Humberto H ^a   Ayala Nuñez, Nilda V ^a   Ixtepan Turrent, Liliana ^a   Rodriguez Padilla, Cristina ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-HIV ACTIVITY; ANTIVIRAL ACTIVITIES; CELL-ASSOCIATED VIRUS; CELL-FREE; CLINICAL ISOLATES; CYTOTOXIC; IN-VITRO; INHIBITORY ACTIVITY; RESISTANT STRAINS; SILVER NANOPARTICLES; VIRAL REPLICATION;

NANOPARTICLES; VIRUSES;

SILVER;

CD4 ANTIGEN; GLYCOPROTEIN GP 120; NANOPARTICLE; SILVER NANOPARTICLE; SILVER NITRATE; SULFADIAZINE SILVER;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PROTEIN BINDING; VIRION; VIRUS ENTRY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 76749144670     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-1     Document Type: Article

References (45)

1. Joint United Nations Programme on HIV AIDS (UNAIDS) Report on the global AIDS epidemic. Geneva, Switzerland 2008, Joint United Nations Programme on HIV AIDS (UNAIDS).
2. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, Vandamme AM, Camacho R. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008, 5:12. 10.1186/1742-4690-5-12, 2265747, 18241328.
3. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003, 100:11013-11018. 10.1073/pnas.1832214100, 196918, 12930892.
4. Borkow G, Lapidot A. Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord 2005, 5:3-15. 10.2174/1568005053174645, 15777194.
5. Al-Jabri AA, Alenzi FQ. Vaccines, Virucides and Drugs Against HIV/AIDS: Hopes and Optimisms for the Future. Open AIDS J 2009, 3:1-3. 10.2174/1874613600903010001, 2644489, 19274070.
6. O'Connor T. Assessment of Activity of Topical Virucidal Agents. Methods in Molecular Medicine, Antiviral Methods and Protocols 2000, 24:207-212. Totowa, NJ: Kinchington, D. and Schinazi, R. F.
7. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 1190212, 15987516.
8. Hoyme UB. Clinical Significance of Crede's Prophylaxis in Germany at Present. Infect Dis Obstet Gynecol 1993, 1:32-36. 10.1155/S1064744993000080, 2364679, 18476203.
9. World Health Organization WHO Model of Essential Medicines. World Health Organization., http://www.who.int/medicines/publications/essentialmedicines/en/index.ht ml
10. Li Y, Leung P, Yao L, Song QW, Newton E. Antimicrobial effect of surgical masks coated with nanoparticles. J Hosp Infect 2006, 62:58-63. 10.1016/j.jhin.2005.04.015, 16099072.
11. Bhattacharya R, Mukherjee P. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev 2008, 60:1289-1306. 10.1016/j.addr.2008.03.013, 18501989.
12. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang CY, Kim YK, Lee YS, Jeong DH, Cho MH. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3:95-101.
13. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF, Che CM. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J Proteome Res 2006, 5:916-924. 10.1021/pr0504079, 16602699.
14. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Tapia J, Yacaman MJ. The bactericidal effect of silver nanoparticles. Nanotechnology 2005, 16:2346-2353.
15. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007, 3:168-171.
16. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 2004, 275:177-182. 10.1016/j.jcis.2004.02.012, 15158396.
17. Sun RW, Rong C, Chung NPY, Ho CM, Lin CLS, Che CM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun 2005, 5059-5061.
18. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 2008, 13:253-262.
19. Sun L, Singh AK, Vig K, Pillai SR, Singh SR. Silver Nanoparticles Inhibit Replication of Respiratory Syncytial Virus. J Biomed Biotechnol 2008, 4:149-158.
20. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. Inhibition of Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles Capped with Mercaptoethane Sulfonate. Bioconjugate Chem 2009, 20:1497-1502.
21. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM. A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque Formation. Nanoscale Research Letters 2008, 3:129-133.
22. Arora S, Jain J, Rajwade JM, Paknikar KM. Cellular responses induced by silver nanoparticles: In vitro studies. Toxicol Lett 2008, 179:93-100. 10.1016/j.toxlet.2008.04.009, 18508209.
23. Kumari A, Kumar P, Ajayan PM, John G. Silver-nanoparticle-embedded antimicrobial paints based on vegetable oil. Nature Materials 2008, 7:236-41. 10.1038/nmat2099, 18204453.
24. Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004, 30(Suppl 1):S1-S9. 10.1016/S0305-4179(04)90000-9, 15327800.
25. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999, 12:147-179. 88911, 9880479.
26. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G, Pannecouque C. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 2000, 58:1100-1108.
27. Yang Q, Stephen AG, Adelsberger JW, Roberts PE, Zhu W, Currens MJ, Feng Y, Crise BJ, Gorelick RJ, Rein AR, Fisher RJ, Shoemaker RH, Sei S. Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4. J Virol 2005, 6122-6133. 10.1128/JVI.79.10.6122-6133.2005, 1091715, 15857997.
28. Bae CH, Nam AH, Park SM. Formation of silver nanoparticles by laser ablation of a silver target in NaCl solution. Appl Surf Sci 2002, 197-198:628-634.
29. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003, 17:653-661. 10.1097/00002030-200303280-00002, 12646787.
30. Lara HH, Ayala-Nuãez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J Microbiol Biotechnol 2009,
31. Neurath AR, Strick N, Li YY, Debnath AK. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001, 1:17. 10.1186/1471-2334-1-17, 57811, 11602021.
32. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003, 51:229-240. 10.1093/jac/dkg079, 12562686.
33. Chavda SC, Griffin P, Han-Liu Z, Keys B, Vekony MA, Cann AJ. Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism. J Gen Virol 1994, 75(Pt 11):3249-3253. 10.1099/0022-1317-75-11-3249, 7964635.
34. Naganawa S, Yokoyama M, Shiino T, Suzuki T, Ishigatsubo Y, Ueda A, Shirai A, Takeno M, Hayakawa S, Sato S, Tochikubo O, Kiyoura S, Sawada K, Ikegami T, Kanda T, Kitamura K, Sato H. Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS One 2008, 3:e3206. 10.1371/journal.pone.0003206, 2527523, 18787705.
35. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
36. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888. 10.1126/science.280.5371.1884, 9632381.
37. Lekutis C, Olshevsky U, Furman C, Thali M, Sodroski J. Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr 1992, 5:78-81.
38. McDonnell GE. Chemical Disinfection. Antisepsis, disinfection, and sterilization 2007, 111-115.
39. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990, 265:10373-10382.
40. Taylor PL, Ussher AL, Burrell RE. Impact of heat on nanocrystalline silver dressings. Part I: Chemical and biological properties. Biomaterials 2005, 26:7221-7229. 10.1016/j.biomaterials.2005.05.040, 16005512.
41. Starodub ME, Trevors JT. Silver resistance in Escherichia coli R1. J Med Microbiol 1989, 29:101-110. 10.1099/00222615-29-2-101, 2659795.
42. Bhol KC, Schechter PJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005, 152:1235-1242. 10.1111/j.1365-2133.2005.06575.x, 15948987.
43. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001, 14:753-77. table., 10.1128/CMR.14.4.753-777.2001, 89002, 11585784.
44. Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997, 71:3023-3030. 191431, 9060662.
45. Ciminale V, Felber BK, Campbell M, Pavlakis GN. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retroviruses 1990, 6:1281-1287.